Pag-regulate sa presyo ng gamot, medisina iniatas ni Digong

Pag-regulate sa presyo ng gamot, medisina iniatas ni Digong

December 8, 2021 @ 10:22 AM 10 months ago


MANILA, Philippines – Inianunsyo ni Acting Presidential Spokesperson at Cabinet Secretary Karlo Nograles ang paglagda ni Pangulong Rodrigo Duterte ng executive order (EO) na magre-regulate sa presyo ng gamot at medisina na gagamitin para tugunan ang pangunahing dahilan ng morbidity o mga sakit sa bansa.

“This is part of efforts to improve access to affordable, quality medicines and reduce the health-related expenses of our countrymen, consistent with the goals of the Universal Health Care Act,” ayon kay Nograles.

Isiniwalat ni Nograles na nilagdaan ni Pangulong Duterte ang EO No. 155, araw ng Martes, Disyembre 7, 2021.

Nakasaad sa EO na ang price regulation via Maximum Retail Price (MRP) at/ o Maximum Wholesale Price (MW) ay ipatutupad sa “34 drug molecules and 71 drug formulas used in agents affecting bone metabolism, analgesics, anesthetics, anti-angina, antiarrhythmics, anti-asthma and chronic obstructive pulmonary disease medicines, antibiotics, anticoagulants, anticonvulsants, antidiabetic drugs, antidiuretics, and antiemetics.”

Sakop din ng EO ang drug molecules at formulas na ginagamit sa anti-glaucoma, anti-hypercholesterolemia medicines, antihypertensive medicines, anti-neoplastic/anti-cancer medicines, antiparkinsons drugs, gamot para sa overactive bladders, growth hormone inhibitors, immunosuppressant drugs, iron chelating agents, at psoriasis, seborrhea at ichthyosis medicines.

Nakasaad naman sa Section 2 ng EO na nire-require ang lahat ng manufacturers, importers, distributors, wholesalers, traders, at retailers para “display the retail price which shall not exceed the MRP.”

Tinukoy din sa EO ang “the MRP, preceded by the words ‘RETAIL PRICE NOT TO EXCEED,’ and ‘UNDER DRUG PRICE REGULATION,’ on a red strip, shall be clearly printed on the label of the immediate container of the drug and medicine and the minimum pack thereof offered for retail.”

Ang listahan ng medisina at kanilang corresponding MRPs at MWPs ay “subject to the review” ng Department of Health (DOH), na may konsultasyon sa Department of Trade and Industry (DTI) anim na buwan mula sa effectivity ng EO, at kada anim na buwan pagkatapos noon.

“Per Section 7 of the EO, violations of the EO shall be dealt with in accordance with RA No. 9502––the Universally Accessible Cheaper and Quality Medicines Act of 2008––and other related laws,” ayon kay Nograles.

Nakasaad din dito na “pursuant to Section 19 of RA No. 9502, the Secretary of Health is directed to investigate alleged violations of the MRP and/or MWP under this Order, impose administrative fines and penalties, and call upon and deputize government entities for assistance necessary to carry out the purpose of this Order.”

Sa ilalim ng Section 19 (D) ng RA No. 9502, ang DOH Secretary ay may kapangyarihan na magpataw ng administrative fines na hindi bababa sa 50,000 piso o mas hihigit naman sa 5,000,000 piso. Kris Jose